Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34results about How to "Lowering blood-glucose" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compositions and methods relating to glucagon receptor antibodies
ActiveUS7947809B2Lowering blood glucoseImprove glucose toleranceMetabolism disorderDigestive systemPrevention of diabetes mellitus type 2Antigen binding
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
Owner:AMGEN INC
Compositions and methods relating to glucagon receptor antibodies
ActiveUS20090041784A1Lowering blood glucoseImprove glucose toleranceImmunoglobulins against cell receptors/antigens/surface-determinantsFermentationPrevention of diabetes mellitus type 2Antigen binding
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
Owner:AMGEN INC
Alpha substituted carboxylic acids
InactiveUS20050187266A1Lower blood pressureLower blood sugar levelsBiocideOrganic chemistryDyslipidemiaBlood lipids
Alpha substituted carboxylic acids of formula (I): wherein R1 and R2 are as defined in the specification and R3 is wherein Y, Ar1, Ar2, Ar3, R4, R5, R6, R7, R8, R9, R9a, R10, R11, R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α / γ related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.
Owner:AGOURON PHARMA INC +1
Alpha substituted carboxylic acids
InactiveUS20050234066A1Lower blood pressureLower blood sugar levelsBiocideOrganic chemistryDyslipidemiaPharmaceutical drug
Alpha substituted carboxylic acids of formula (I): wherein R1 and R2 are as defined in the specification and R3 is wherein Y, Ar1, Ar2, Ar3, R4, R5, R6, R7, R8, R9, R9a, R10, R11, R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α / γ related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.
Owner:AGOURON PHARMA INC
Konjac mannan and ginseng compositions and methods and uses thereof
InactiveUS20050020535A1Improve treatment outcomesLowering blood-glucosePowder deliveryBiocideNitric oxideAmorphophallus
Described are a number of compositions, namely a konjac mannan mixture, a ginseng composition, and a composition comprising konjac mannan and American ginseng. Methods of use of these compositions are described including their use for reducing blood glucose in non-diabetic and diabetic individuals, as well as reducing postprandial blood glucose in such individuals. Applications in the treatment of hyperlipidemia, high blood pressure, an increase in nitric oxide, Syndrome X and cardiovascular disease are also described. Various other applications of the compositions and methods are also described.
Owner:VUKSAN HLDG
Kinase inhibitors for the treatment of diabetes and obesity
InactiveUS20060094682A1Increase insulin sensitivityLowering blood-glucoseCompound screeningSenses disorderPyrazolopyrimidineDisease
The present invention discloses a method of treating an individual or animal with diabetes and / or obesity. The method comprises administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor. Preferably, the preventative and therapeutic methods of the present invention involve administering—to a mammal in need thereof—a therapeutically effective amount of an inhibitor of a c-Src-family protein tyrosine kinase. The invention pertains to pharmaceutical compositions containing an inhibitor of a c-Src-family protein tyrosine kinase or an analog or metabolite thereof, or an inhibitor of another protein tyrosine kinase, and a pharmaceutically acceptable carrier. Purines and pyrimidines and other molecules useful in the treatment of diabetes and obesity are provided herein, in particular, pyrazolopyrimidines, cyanoquinolines, phenylaminopyrimidines, anilinoquinazolines and related compounds. The invention also provides cellular targets and assay compositions useful for the identification of additional novel therapeutic agents for the treatment of these disorders.
Owner:ODYSSEY THERA INC
Glp-1 and fgf21 combinations for treatment of diabetes type 2
InactiveUS20120172298A1Remarkable effectImprove survivabilityPeptide/protein ingredientsMetabolism disorderGlycemicFGF21
The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21) compound and a Glucagon-Like Peptide 1 (GLP-1) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db / db mice in vivo.
Owner:NOVO NORDISK AS
Method for Decreasing Blood Glucose Levels
InactiveUS20070231273A1Lower blood sugar levelsFacilitated releaseBiocidePill deliveryGlucose polymersD-Glucose
A method for decreasing blood glucose levels is disclosed. Iptakalim hydrochloride (a SUR1 subunit-dependent KATP channel blocker and a SUR2 subunit-selective KATP channel opener) is used to block pancreatic β-cell KATP channels, which depolarizes β-cells, elevates intracellular Ca2+ concentrations, and in turn increases insulin release. Therefore, in some implementations, iptakalim hydrochloride is an optimal treatment for type-2 diabetic patients with cardiovascular disorders.
Owner:WU JIE
Glucagon receptor antagonists, preparation and therapeutic uses
ActiveUS7816557B2Inhibitory responseLower blood sugar levelsOrganic active ingredientsOrganic chemistryDiabetes mellitusMedicine
The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
Owner:ELI LILLY & CO
N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
ActiveUS8076377B2Good effectLowering blood glucoseOrganic active ingredientsBiocideSolubilityCoronary artery disease
Owner:HANALL PHARMA CO LTD
Konjac-mannan and ginseng compositions and methods and uses thereof
InactiveUS7326404B2Improve treatment outcomesLowering blood-glucosePowder deliveryBiocideNitric oxideAmorphophallus rivieri
Owner:VUKSAN HLDG
Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
InactiveUS20050113314A1Lower blood pressureReducing platelet aggregationBiocideSenses disorderCombined Modality TherapyCombination therapy
Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing complications in patients with diabetes and / or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and / or preventing complications (including microalbuminuria, nephropathies, retinopathies and other complications) in patients with diabetes or metabolic syndrome.
Owner:COTHERIX INC
Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses
InactiveUS20110195139A1Lowering blood-glucoseIncrease insulin levelsBiocideMetabolism disorderIncreased insulin levelGlucose polymers
The present invention is related to the use of an overground part of Hedychium coronarium Koenig in lowering blood glucose, increasing insulin levels and treating and / or preventing diabetes without overly reducing blood glucose in a subject; i.e., not reducing blood glucose in a fasting subject. The present invention also relates to an extract and composition of the overground part of Hedychium coronarium Koenig and its use in lowering blood glucose, increasing insulin levels and treating and / or preventing diabetes.
Owner:DEV CENT FOR BIOTECHNOLOGY
Biguanide derivative and therapeutic agent for diabetes containing the same
InactiveUS20050124693A1Suppresses elevation in blood glucose levelLower blood sugar levelsBiocideNervous disorderHydrogenMedicinal chemistry
Diabetes treatments comprising, as effective ingredients, biguanide derivatives represented by the following general formula (1), or salts thereof. (wherein R1, R2 and R3 may be the same or different and each represents one selected from the group consisting of hydrogen, optionally substituted lower alkyl groups and optionally substituted lower alkylthio groups).
Owner:CHUGAI PHARMA CO LTD
Plasma Anti-diabetic nucb2 peptide (pladin) and uses thereof
ActiveUS20100235935A1Inhibitory effectInhibit anti diabetic effectOrganic active ingredientsBiocidePeptideBlood plasma
The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.
Owner:LANDING BIOTECH
Use of composition containing iron (II) amino acid chelate in preparation of drug for ameliorating diabetes
InactiveUS20170007568A1Good effectLowering blood-glucoseOrganic active ingredientsHeavy metal active ingredientsDiabetes mellitusD-Glucose
The present invention provides a use of a composition containing a ferrous amino acid chelate for the preparation of a pharmaceutical used in diabetes improvement. The pharmaceutical comprise an effective amount of the composition containing the ferrous amino acid chelate and pharmaceutically acceptable carriers to improve diabetes. The amino acid is able to be chelated with the ferrous iron in a chelated state stably as passing through the stomach. The composition containing the ferrous amino acid chelate can effectively lower blood glucose and improve insulin sensitivity. The pharmaceutical prepared by the composition containing the ferrous amino acid chelate have effect on diabetes improvement.
Owner:PROFEAT BIOTECH
Nonpeptide insulin receptor agonists
InactiveUSRE38915E1Lowering blood-glucoseBiocideHydrocarbon active ingredientsDiabetes mellitusProton
Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula whereineach A is independently a proton-accepting substituent;each R is independently a noninterfering substituent;n is 0, 1, or 2; andeach linker is independently an isostere of —NHCONH— or of —N═N— or of —NHCO—.Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.
Owner:TELIK INC
Acylated derivative of human insulin or analogue thereof
ActiveUS20190169257A1Improve stabilityLong lastingPeptide/protein ingredientsMetabolism disorderInsulin activityZinc
Provided is an acylated derivative of human insulin or an analogue thereof. Specifically disclosed is an acylated derivative of a human insulin analogue, or zinc complex thereof; said acylated derivative is longer-lasting than existing insulin analogues and acylated derivatives thereof, its blood glucose reduction is more steady, and it is more stable in storage.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
Lipin1 function
InactiveUS20050260709A1Lowering blood-glucoseReduce the amount requiredObesity gene productsPeptide/protein ingredientsBiologyDiabetes mellitus
The present invention addresses the mechanistic role of Lipin1 in the absence of embryonic development. Accordingly, the present invention relates to novel Lipin1 polypeptides and nucleic acids encoding these polypeptides, which polypeptides are involved in body-weight regulation, energy homeostasis, metabolism, obesity, and diabetes. Furthermore, the invention provides substances modulating the function of the polypeptides of the invention, in particular siRNAs inhibiting Lipin1 function in general and Lipin1B2 function in particular and the medical uses of Lipin1 activators and inhibitors.
Owner:DEVELOGEN AKTIENGES
Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia
InactiveUS20160375020A1Induce serum insulin levelIncrease insulin sensitivityBiocideMetabolism disorderAcute hyperglycaemiaFatty liver
The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
Owner:PEKING UNIV THIRD HOSPITAL
Modulation of chrebp expression
InactiveUS20090209625A1Lowering blood glucoseReduce cholesterolOrganic active ingredientsBiocideDiseaseMedicine
Disclosed herein are compounds, compositions, and methods for modulating the expression of ChREBP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and conditions.
Owner:IONIS PHARMA INC
Oxyntomodulin analogue
ActiveUS10479819B2No adverse eventsLong half-lifeCosmetic preparationsPeptide-nucleic acidsDiabetes mellitusAdverse drug reaction
Owner:JIANG XIANXING
Plasma Anti-diabetic NUCB2 peptide (pladin) and uses thereof
ActiveUS20140005105A1Inhibitory effectInhibit anti diabetic effectBiocideOrganic active ingredientsPeptideBlood plasma
The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.
Owner:LANDING BIOTECH
IL-25 treatment of obesity and metabolic disorders
InactiveUS9724392B2Reduce weightAvoid weight gainPeptide/protein ingredientsMetabolism disorderWhite blood cellWeight gain
Owner:UNIV OF MARYLAND BALTIMORE
GPR120 receptor agonists and uses thereof
InactiveUS8309600B2Promote insulin secretionLowering blood glucoseBiocideOrganic chemistryDiseaseAgonist
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
Owner:CYMABAY THERAPEUTICS
Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof
ActiveUS9018159B2Improved diabetic symptomSuppress food intakeOrganic active ingredientsPeptide/protein ingredientsDiabetes mellitusPlasmin Inhibitors
The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.
Owner:LANDING BIOTECH
Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
InactiveUS20110071111A1Eliminate side effectsEnhance tissue sensitivityBiocideSenses disorderBlood lipidsHypolipidemic Drugs
Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing complications in patients with diabetes and / or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and / or preventing complications (including microalbuminuria, nephropathies, retinopathies and other complications) in patients with diabetes or metabolic syndrome.
Owner:FONG BENSON M +1
N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
ActiveUS20100249241A1Good effectIncrease insulin sensitivityOrganic active ingredientsBiocideSolubilityRhabdomyolysis
Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.
Owner:HANALL PHARMA CO LTD
Methods of treating obesity and related disorders using tellurium selenium compounds
The present invention relates to methods of using tellurium and selenium containing compounds, and particularly to the use of small organic molecules containing tellurium or selenium as exemplified by the compound ammonium-trichloro(dioxoethylene-O,O′)tellurate (known by the abbreviation AS101) for treating obesity and obesity related disorders or complications and for reducing of food intake.
Owner:BIOMAS
Probucol derivative, preparation method therefor and use thereof
ActiveUS20210040052A1Outstanding therapeuticOutstanding relieving effectSenses disorderOrganic chemistryDiseaseTG - Triglyceride
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol derivative provided in the present invention can be used for the prevention and treatment of vascular diseases including diabetes, cardio-cerebrovascular diseases or complications thereof, and can be effectively used for reducing blood glucose, reducing blood lipid, reducing cholesterol, reducing body weight, reducing triglyceride, anti-inflammatory, and anti-oxidation, etc., having broad prospective applications.
Owner:DEMOTECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com